Evidence map›Paper›PMID 37551650›Full record

ArticleThe International journal of eating disorders2023

"But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy.

Amanda E Downey, Maxine Boyd, Anita V Chaphekar, Joshua Woolley, Marissa Raymond-Flesch

Open access · hybridAbstract read
In one paragraph

Article in The International journal of eating disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Amanda E DowneyDepartment of Pediatrics, University of California, San Francisco, California, USA.ORCID 0000-0002-5206-7798
Maxine BoydDepartment of Psychological Science, Loyola Marymount University, Los Angeles, California, USA.
Anita V ChaphekarDepartment of Pediatrics, University of California, San Francisco, California, USA.
Joshua WoolleyDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Marissa Raymond-FleschDepartment of Pediatrics, University of California, San Francisco, California, USA.
University of California, San Francisco · USLoyola Marymount University · USSan Francisco VA Medical Center · US

Funding

Institutional Career Development Core SupplementKL2TR001870 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SARKAR, URMIMALA · 2016 to 2025
$19.7M
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9M
CSRD VA IK4 CX002090Mary Rita Crittenden Fund at the University of California San Francisco, Division of Adolescent and Young Adult MedicineNCATS NIH HHS KL2 TR001870
6 · The paper itself

Abstract

objectiveThis study invited providers who care for patients with eating disorders to inform engagement, communication, and collaboration with psilocybin-assisted psychotherapy interventions.

methodMedical and mental health providers who treat patients with eating disorders were recruited via professional referral networks and participant driven sampling from across California to participate in one of five focus groups. Discussion topics included prior knowledge of psychedelic therapy, interest/concerns related to psilocybin therapy, and opportunities for collaboration. Study team members completed iterative rounds of coding with a grounded theory approach.

resultsA total of 32 participants reported a range of familiarity with psychedelics. Some raised concerns about the risks of administering psilocybin to malnourished patients and to those with psychological comorbidities. Despite these concerns, participants were hopeful to see psilocybin therapy as a treatment for patients with eating disorders. In anticipating challenges, providers had concerns about equity in access to care among publicly insured and non-English speaking patients. They requested opportunities for continuing education about psilocybin therapy. DISCUSSION: Our findings demonstrate provider interest in psilocybin therapy for the treatment of patients with eating disorders. As psilocybin therapy interventions are developed, providers caring for patients with eating disorders value collaboration to improve longitudinal patient outcomes. PUBLIC SIGNIFICANCE: This study invited healthcare providers of patients with eating disorders to discuss their thoughts around the use of psilocybin-assisted psychotherapy in this population. Findings will help inform emerging psilocybin therapy clinical trials with the goal of successful translation and adoption in real world clinical settings.

Indexed as

Feeding and Eating DisordersPsilocybinFocus GroupsHumansPsychotherapyQualitative ResearchPsilocybinanorexia nervosaeating disorderspsilocybinpsychedelic-assisted psychotherapy

Identifiers

PMID37551650
PMCPMC12965192
OpenAlexW4385664009

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.